Cargando…
Baricitinib and primary biliary cholangitis
BACKGROUND AND AIMS: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA). A proof-of-concept study of baricitinib, an orally administered Janus kinase 1 and 2 inhibitor, was initiated t...
Autores principales: | Gordon, Stuart C., Trudeau, Sheri, Regev, Arie, Uhas, Jonathan M., Chakladar, Sujatro, Pinto-Correia, Ana, Gottlieb, Klaus, Schlichting, Doug |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240017/ https://www.ncbi.nlm.nih.gov/pubmed/34195587 http://dx.doi.org/10.1016/j.jtauto.2021.100107 |
Ejemplares similares
-
Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021) -
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis
por: Lu, Mei, et al.
Publicado: (2020) -
Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018) -
Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018) -
Primary Biliary Cholangitis: A Case of Underdiagnosis
por: Garcês Soares, Sofia, et al.
Publicado: (2021)